JP2016523260A5 - - Google Patents

Download PDF

Info

Publication number
JP2016523260A5
JP2016523260A5 JP2016521898A JP2016521898A JP2016523260A5 JP 2016523260 A5 JP2016523260 A5 JP 2016523260A5 JP 2016521898 A JP2016521898 A JP 2016521898A JP 2016521898 A JP2016521898 A JP 2016521898A JP 2016523260 A5 JP2016523260 A5 JP 2016523260A5
Authority
JP
Japan
Prior art keywords
pruritus
serlopitant
octahydroisoindol
cyclopent
polymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016521898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523260A (ja
Filing date
Publication date
Priority claimed from US13/925,509 external-priority patent/US8906951B1/en
Application filed filed Critical
Priority claimed from PCT/US2014/043811 external-priority patent/WO2014209962A1/en
Publication of JP2016523260A publication Critical patent/JP2016523260A/ja
Publication of JP2016523260A5 publication Critical patent/JP2016523260A5/ja
Ceased legal-status Critical Current

Links

JP2016521898A 2013-06-24 2014-06-24 そう痒におけるnk−1受容体アンタゴニストのセルロピタントの使用 Ceased JP2016523260A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361838784P 2013-06-24 2013-06-24
US61/838,784 2013-06-24
US13/925,509 US8906951B1 (en) 2013-06-24 2013-06-24 Use of NK-1 receptor antagonists in pruritus
US13/925,509 2013-06-24
PCT/US2014/043811 WO2014209962A1 (en) 2013-06-24 2014-06-24 Use of nk-1 receptor antagonist serlopitant in pruritus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019087897A Division JP2019142960A (ja) 2013-06-24 2019-05-07 そう痒におけるnk−1受容体アンタゴニストのセルロピタントの使用

Publications (2)

Publication Number Publication Date
JP2016523260A JP2016523260A (ja) 2016-08-08
JP2016523260A5 true JP2016523260A5 (enExample) 2017-08-03

Family

ID=51230173

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016521898A Ceased JP2016523260A (ja) 2013-06-24 2014-06-24 そう痒におけるnk−1受容体アンタゴニストのセルロピタントの使用
JP2019087897A Pending JP2019142960A (ja) 2013-06-24 2019-05-07 そう痒におけるnk−1受容体アンタゴニストのセルロピタントの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019087897A Pending JP2019142960A (ja) 2013-06-24 2019-05-07 そう痒におけるnk−1受容体アンタゴニストのセルロピタントの使用

Country Status (13)

Country Link
EP (1) EP3013336A1 (enExample)
JP (2) JP2016523260A (enExample)
KR (1) KR20160023692A (enExample)
CN (1) CN105473138A (enExample)
AU (2) AU2014302694B2 (enExample)
BR (1) BR112015031724A2 (enExample)
CA (1) CA2915474A1 (enExample)
HK (1) HK1223820A1 (enExample)
IL (1) IL243189A0 (enExample)
MX (2) MX366728B (enExample)
PH (2) PH12015502777A1 (enExample)
RU (1) RU2666219C2 (enExample)
WO (1) WO2014209962A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
JP6741655B2 (ja) 2014-09-19 2020-08-19 ヘロン セラピューティクス, インコーポレイテッドHeron Therapeutics, Inc. アプレピタントのエマルジョン製剤
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
CA3013288A1 (en) * 2016-02-01 2017-08-10 Heron Therapeutics, Inc. Emulsion comprising an nk-1 receptor antagonist
US9974742B2 (en) 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
KR20190039936A (ko) * 2016-06-29 2019-04-16 멘로 쎄라퓨틱스 인크. 다양한 소양증성 병태를 치료하기 위한 뉴로키닌-1 길항제의 용도
CA3073998A1 (en) * 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
US11426408B2 (en) * 2017-11-01 2022-08-30 National University Of Singapore Use of serotonergic drugs to treat virus-induced thrombocytopenia
WO2019152232A1 (en) * 2018-01-31 2019-08-08 Twi Pharmaceuticals, Inc. Topical formulations comprising tofacitinib
CN115015440B (zh) * 2022-07-08 2024-10-15 江苏杜瑞制药有限公司 一种生物样品中纳呋拉啡的检测方法
CN117503699A (zh) * 2023-12-08 2024-02-06 斯坦德医药研发(江苏)有限公司 阿瑞匹坦口服液制剂及制剂制造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100565A1 (en) 2001-09-21 2003-05-29 Boehringer Ingelheim International Gmbh Method for the treatment or prevention of atopic dermatitis
CN100582093C (zh) * 2004-01-27 2010-01-20 默克公司 氢异二氢吲哚速激肽受体拮抗剂
AR047439A1 (es) 2004-01-27 2006-01-18 Merck & Co Inc Antagonistas del receptor hidroisoindolina taquiquinina
DE602006020450D1 (de) 2005-07-11 2011-04-14 Merck Sharp & Dohme Ykinin-rezeptorantagonisten
WO2007044296A2 (en) 2005-10-04 2007-04-19 Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
WO2007146224A2 (en) 2006-06-12 2007-12-21 Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
AU2007293393A1 (en) 2006-09-06 2008-03-13 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
EP2089019A4 (en) 2006-11-02 2011-05-04 Merck Sharp & Dohme POLYMORPHIC OF A HYDROISOINDOLINE TACHYKININE RECEPTOR ANTAGONIST
US20100113469A1 (en) 2007-03-29 2010-05-06 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
RU2370265C1 (ru) * 2008-03-04 2009-10-20 Лев Давидович Раснецов Гель, обладающий противовоспалительным и противоаллергическим действием

Similar Documents

Publication Publication Date Title
JP2016523260A5 (enExample)
CY1124669T1 (el) ΑΝΤΙ-ΟΙΣΤΡΟΓΟΝΙΚΑ ΦΑΡΜΑΚΑ ΤΕΤΡΑΫΔΡΟ-1Η-ΠΥΡΙΔΟ[3,4-b]INΔOΛIOY
JP2017186358A5 (enExample)
JP2016518337A5 (enExample)
JP2014156468A5 (enExample)
JP2013519675A5 (enExample)
EP4663636A3 (en) Trifluoromethyl substituted pyrazoles as human plasma kallikrein inhibitors
JP2016515522A5 (enExample)
JP2016539157A5 (enExample)
JP2016535795A5 (enExample)
JP2017035491A5 (ja) 頭蓋内出血の治療のための方法および装置
JP2015024998A5 (enExample)
CY1118839T1 (el) Επικαλυμμενη φαρμακευτικη συνθεση που περιεχει ρεγοραφενιμπη
EA201692436A1 (ru) Медицинское применение
EA201591291A1 (ru) Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания
JP2013543896A5 (enExample)
JP2015504870A5 (enExample)
JP2015078220A5 (enExample)
JP2013173781A5 (enExample)
JP2011148799A5 (enExample)
EA201391485A1 (ru) Способы и композиции для лечения нейродегенеративных заболеваний
JP2016522254A5 (enExample)
JP2015199738A5 (enExample)
IL263004B (en) A new crystalline form of n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4 -ilamino)-benzamide
CY1121988T1 (el) Θεραπευτικη αγωγη της πολλαπλης σκληρυνσης